Four-tier evidence classification chart for research and clinical peptides comparing Tier 1 FDA-approved RCTs, Tier 2 human mechanism/PK studies, Tier 3 pre-clinical/emerging evidence, and Tier 4 weak/insufficient evidence
THE FOUR TIERS OF PEPTIDE EVIDENCE: Separating compounds with FDA approval or multiple published human randomized controlled trials (Tier 1) from those with human clinical/PK studies (Tier 2), animal/emerging models (Tier 3), or weak/insufficient human evidence (Tier 4).

The Evidence Hierarchy Applied

“Do peptides work?” is a question that cannot be answered honestly without first specifying which peptide and for which indication (NIH: Peptide Therapeutics Overview). The biomedical literature does not treat “peptides” as a single efficacy category; it evaluates individual compounds with individual mechanisms. Short answer: some do, some do not, and many sit in the gap between encouraging animal data and unproven human outcomes.

A low mesa beneath broad layers of bright desert cloud
Figure 2: Weighing clinical evidence requires separating multi-center human randomized controlled trials and human pharmacokinetic studies from pre-clinical rodent and cell-culture experiments.

Compound-by-Compound Evidence Matrix

Below is our structured grading of the compounds most commonly discussed across clinical and research-peptide literature, comparing their primary claimed use against human clinical evidence, animal/in-vitro evidence, and overall editorial verdict.

Compound Primary Claim / Common Context Human Evidence Animal / Pre-Clinical Evidence Evidence Tier & Editorial Verdict
Semaglutide Weight management, glycemic control Extensive RCT data (STEP, SUSTAIN trials) and massive real-world clinical data Pre-clinical evidence not specified in this comparison Tier 1 · Established (FDA-Approved)
Tirzepatide Weight management, glycemic control RCT programs (SURMOUNT, SURPASS) and accumulating real-world clinical data Pre-clinical evidence not specified in this comparison Tier 1 · Established (FDA-Approved)
Tesamorelin Visceral fat reduction (HIV-associated lipodystrophy) FDA-approved (Egrifta); multiple published human RCTs (PubMed: Tesamorelin Clinical Efficacy); off-label data in healthy adults is limited Extensive receptor and toxicology studies Tier 1 · Proven for Labeled Indication
Ipamorelin GH release, recovery Human clinical/PK studies show GH elevation (PubMed: Ipamorelin Clinical Study) Strong animal data on selective GH release Tier 2 · Mechanism Confirmed; Outcome Benefit Unclear
CJC-1295 No DAC Pulsatile GH release Multiple human GHRH(1-29) analog studies showing pulsatile GH elevation Strong animal data Tier 2 · Strong Mechanism Evidence
CJC-1295 With DAC Sustained GH/IGF-1 elevation Phase I/II human PK data exists; limited outcome trials and side-effect/prolactin questions Animal data Tier 2 · PK Established; Clinical Outcome Unproven
GHRP-2 GH release, appetite signaling Human clinical endocrine data exists showing GH elevation Extensive animal GH secretagogue studies Tier 2 · Good Endocrine Evidence
GHRP-6 GH release, appetite stimulation Human clinical studies demonstrating GH release and ghrelin-mimetic appetite effects Extensive animal studies Tier 2 · Good Endocrine Evidence
Gonadorelin LH/FSH stimulation Clinical use for hypogonadism Animal data Tier 2 · High Confidence for Specific Indication
GHK-Cu Skin/wound remodeling Small human dermatology RCTs, mostly topical; injectable human evidence lacking In-vitro and animal wound-healing studies Tier 2 · Modest Topical Evidence
SS-31 / Elamipretide Mitochondrial protection FDA Phase II/III trials ongoing Mechanism well-characterized Tier 2 · Active Clinical Development
BPC-157 Soft-tissue healing, gastrointestinal protection Zero published randomized placebo-controlled human trials Extensive positive rat tendon, muscle, and GI data Tier 3 · Plausible in Animals; Unproven in Humans
TB-500 Soft-tissue repair, inflammation None in humans for the marketed synthetic TB-500 fragment Animal model support (often using full-length Tβ4) Tier 3 · Plausible; Fragment Human Data Absent
Thymosin Beta-4 (Full-Length) Tissue repair Very limited human evidence Animal tissue-repair and cell-migration studies Tier 3 · Limited Human Data; High Synthesis Cost
Kisspeptin Reproductive hormone regulation Emerging human endocrine research Strong animal neuroendocrine data Tier 3 · Emerging Research
LL-37 Immune / antimicrobial activity Limited clinical data In-vitro antimicrobial and animal wound studies Tier 3 · Low-Moderate Evidence
MOTS-c Metabolic / endurance signaling Effectively no human clinical outcome data Mitochondrial mechanism data in cells and animals Tier 3 · Mechanistically Interesting; Unproven
Melanotan-II Skin pigmentation / tanning Small dermatology studies Melanocortin receptor studies Tier 3 · Effect Real; Safety Profile Concerning
MGF (Mechano Growth Factor) Direct muscle growth No human clinical trials Limited cell and rodent data Tier 4 · Questionable / Insufficient Evidence
PEG-MGF Extended muscle growth No human clinical data Minimal pre-clinical data Tier 4 · Questionable / Insufficient Evidence
Epitalon Anti-aging / telomere claims None convincing in humans Russian-language studies, methodologically thin Tier 4 · Weak Evidence; Substantial Hype
“Anti-Aging” Peptide Stacks General longevity None on the combined stack itself None on the combined stack itself Tier 4 · Marketing Construct
Source: Wild West & Peptides Compound Evidence Audit (October 2026).

What “Works” Means Operationally

Most published peptide research uses surrogate endpoints—biomarkers, imaging changes, or animal-model behavioral outcomes—rather than clinical outcomes that patients and researchers actually care about. A compound that increases growth hormone secretion in rats may or may not produce any noticeable change in human body composition, athletic performance, or injury recovery. The leap from mechanism to clinical outcome is exactly where most peptide hype lives.

The analytical defense, for any compound, is to ask three sequential questions:

  1. Does it do what is mechanistically claimed? (For example, does Ipamorelin actually elevate growth hormone in humans?)
  2. Does the mechanism produce the downstream effect that matters? (Does GH elevation of that magnitude and duration produce a meaningful body-composition or recovery change?)
  3. Is the effect large enough and durable enough to matter relative to placebo and to the side-effect profile?

Many peptides clear Question 1 and stall at Question 2 or Question 3. Ipamorelin does elevate GH (PMID 17312170). Whether that GH elevation produces measurable body-composition change in a healthy adult is much less clear, and whether any change is durable beyond cessation is even less clear. Honest reporting requires keeping those three questions separate.

Why the Marketing Gets So Far Ahead of the Evidence

Peptide marketing is structurally biased toward overstatement because of three intersecting incentives:

  • Regulatory Framing at Point of Sale: Because research peptides are sold as non-clinical “research chemicals” rather than approved prescription medicines, vendors often push promotional narratives that would never pass FDA prescription-drug labeling review.
  • Audience Confirmation Bias: Buyers searching for research peptides are often already motivated to try a compound, so marketing copy that confirms efficacy converts better than copy that explains evidentiary gaps.
  • Zero-Cost Claim Replication: Once one vendor blog describes a compound as a “proven tissue regenerator,” dozens of competing storefronts repeat the claim within months without citing a single new clinical trial.

The Placebo Problem Is Real

For any subjectively reported outcome—pain reduction, sleep quality, mood improvement, or recovery sensation—the placebo effect is substantial. Sham-injection studies in non-peptide medical research have measured placebo response rates of 20% to 40% for chronic pain endpoints, compounded by financial commitment, community reinforcement, and concurrent changes in diet or rest. Compounds backed by objective endpoints—such as visceral fat reduction in Tesamorelin clinical trials (PMID 22217375), or weight and glycemic endpoints in Semaglutide and Tirzepatide trials—demonstrate effects clearly above placebo. Compounds supported only by unblinded “I felt better” forum reports may or may not operate above placebo until a blinded controlled human trial is conducted.

Bottom Line: Effectiveness Hierarchy Summary

  • Proven in Human Clinical Trials (Tier 1): Semaglutide and Tirzepatide (weight and glycemic control) and Tesamorelin (visceral fat reduction in HIV-associated lipodystrophy).
  • Mechanism Confirmed in Humans, Outcome Context Specific (Tier 2): Ipamorelin, CJC-1295, GHRP-2, GHRP-6 (GH elevation), Gonadorelin (LH/FSH stimulation), topical GHK-Cu (small dermatology studies), and SS-31 / Elamipretide (active Phase II/III trials).
  • Plausible Pre-Clinical Signal, Unproven in Human RCTs (Tier 3): BPC-157, TB-500, full-length Thymosin Beta-4, Kisspeptin, LL-37, MOTS-c, and Melanotan-II (real pigmentation effect, concerning safety profile).
  • Questionable or Insufficient Evidence (Tier 4): MGF, PEG-MGF, Epitalon, and multi-compound “anti-aging stacks.”

External References

Related Desk Reports